Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
REPTT is an observational, prospective, multi-country, multicentre and non-interventional registry in which at least 300 patients with Thrombotic thrombocytopenic purpura (TTP) in Spain and Portugal will be evaluated.
The study will be carried out in the context of the usual clinical practice conditions, not imposing restrictions on the participating physician or influencing their normal clinical practice.
TTP is a rare life-threatening haematological disease characterised by thrombotic microangiopathy (TMA) with an average annual prevalence of approximately 10 cases/million people worldwide and an annual incidence between 1.5 and 6.0 cases per million according to different studies conducted in France, the United States and in the United Kingdom. In Spain the incidence is 2,67 cases / million population per year.
Acute TTP episodes cause sequelae like vascular disease or kidney damage along with other symptoms more subtle like small neurocognitive deficits and myocardial infarction.
Thus, prompt resolution of acute episodes along with a better understanding of the cardiac abnormalities may allow to prevent further complications, to develop targeted rehabilitation techniques for TTP patients and to improve their quality of life.
This project will collect a big database capable of providing better answers to questions related with treatment efficacy, associated morbidity and mortality, and the possible neurocognitive and cardiac sequelae derived from relapses and acute episodes. Additionally, this project will be linked to obtaining biological samples for a serum and DNA library from patients with TTP.
Patients will be recruited by medical researchers specialized in haematology or by other investigators specialized in thrombotic microangiopathies disease management. This recruitment will be performed in a competitive manner. The collection period will be at least 3 years with the possibility of extending it.
REPTT aims to evaluate new scores and prognostic factors of morbidity and mortality in TTP patients.
The final aim is to establish guidelines and recommendation to improve the global management, diagnosis and treatment of patients with TTP in real-life.
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Thrombotic thrombocytopenic purpura patients | Including all patients enrolled in the study |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Standard clinical practice | Other | The study will be carried out in the context of the usual clinical practice conditions, not imposing restrictions on the participating physician or influencing their normal clinical practice. |
| Measure | Description | Time Frame |
|---|---|---|
| Incidence of TTP in Spain/Portugal | Number of patients diagnosed with TTP and enrolled in the registry per year | Throughout the study period, calculated for the 3 years of expected duration. |
| Morbidity of TTP in Spain/Portugal | Percentage of patients diagnosed with TTP and enrolled in the registry among spanish / portuguese population per year | Throughout the study period, calculated for the 3 years of expected duration. |
| Mortality of TTP in Spain/Portugal | Percentage of patients diagnosed with TTP and enrolled in the registry per year who died due to the disease | Throughout the study period, calculated for the 3 years of expected duration. |
| Measure | Description | Time Frame |
|---|---|---|
| Clinical response to treatment rate | Defined as sustained normalization of platelet counts above the lower limit of the established reference range and of lactate dehydrogenase (LDH) after cessation of plasma exchange. The number of patients that achieved clinical response and their frequency will be reported. | Throughout the study period, approximately 3 years per patient |
Not provided
Inclusion Criteria:
Note: Decision was taken to treat the patient with an specific treatment prior and independently of patient inclusion in this non interventional study.
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Patients diagnosed with Thrombotic thrombocytopenic purpura (TTP)
| Name | Role | Phone | Extension | |
|---|---|---|---|---|
| Contact person Designated by the Sponsor | Contact | +34934344412 | investigacion@mfar.net |
| Name | Affiliation | Role |
|---|---|---|
| Dr. María Eva Mingot Castellano, M.D. Ph.D. | Hospital Universitario Virgen del Rocío. Sevilla, España. | Study Chair |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Hospital Universitario Virgen del Rocío | Recruiting | Seville | Andalusia | 41013 | Spain |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| D011696 | Purpura, Thrombocytopenic |
| D011697 | Purpura, Thrombotic Thrombocytopenic |
| ID | Term |
|---|---|
| D011693 | Purpura |
| D001778 | Blood Coagulation Disorders |
| D006402 | Hematologic Diseases |
| D006425 | Hemic and Lymphatic Diseases |
Not provided
Not provided
Not provided
Not provided
Not provided
This project will be linked to obtaining biological samples for a serum and DNA library from patients with TTP, to study the impact of the molecular / biological factors on the short and long-term prognosis.
| TTP Clinical remission rate | Defined as a clinical response after cessation of plasma exchange, maintained for > 30 days. The number of patients that achieved clinical remission and their frequency will be reported | Throughout the study period, approximately 3 years per patient |
| TTP Exacerbation rate | Defined as a reduction in platelet count to below the lower limit of the established reference range, an increased LDH level, and the need to restart plasma exchange within 30 days of the last plasma exchange after a clinical response to plasma exchange. The number of patients with exacerbations and their frequency will be reported | Throughout the study period, approximately 3 years per patient |
| TTP Relapse rate | Defined as a fall in platelet count to below the lower limit of the established reference range, with or without clinical symptoms, > 30 days after stopping of plasma exchange for an acute TTP episode, requiring reinitiation of therapy. This is usually associated with a new increase in the LDH level. The number of patients with relapse and their frequency will be reported. | Throughout the study period, approximately 3 years per patient |
| Refractory TTP rate | defined as persistent thrombocytopenia, lack of a sustained platelet count increment or low platelet counts and a persistently raised LDH level despite five plasma exchanges 44 and steroid treatment. The number of patients with refractory TTP and their frequency will be reported. | Throughout the study period, approximately 3 years per patient |
| Time-to-response (TTR) | Defined as the time from the date of first administration of treatment until the date of clinical response. Patients who die, are lost to follow-up, or reach the time point of analysis without a known record of response will have the TTR censored at the date of death, last assessment or last contact of a follow-up, whichever occurs last. Patients who received a new treatment for TTP whatever the type of treatment before disease response will be censored at the start date of this new treatment. The cumulative incidence of TTR will be estimated by the method of Kaplan-Meier. | Throughout the study period, approximately 3 years per patient |
| Duration of response (DoR) | DoR will be calculated among those patients that achieve a clinical response from the time that measurement criteria are first met until the date of exacerbation, relapse, appearance of refractory TTP or death by any cause. Patients who are lost to follow-up, or reach the time point of analysis without a known record of TTP recurrence or death will have the DoR censored at the date of last assessment or last contact of a follow-up, whichever occurs last. Patients who received a new treatment for TTP, whatever the type of treatment, will be censored at the start date of this new treatment. | Throughout the study period, approximately 3 years per patient |
| Relapse-free survival (RFS) | RFS will be calculated from the date of first administration of treatment until the date of TTP relapse or the date of death due to any cause. Patients who are lost to follow-up, or reach the time point of analysis without a known record of relapse or death will have the RFS censored at the date of last assessment or last contact, whichever occurs last. Patients who received a new treatment for TTP, whatever the type of treatment, before disease relapse or death will be censored at the start date of this new treatment. The cumulative incidence of relapse will be estimated by the method of Kaplan-Meier | Throughout the study period, approximately 3 years per patient |
| Overall survival (OS) | OS will be calculated from the date of the first episode recorded until the date of death due to any cause. Patients who are lost to follow-up or reach the time point of analysis without a known record of death will have the OS censored at the date of last contact. The cumulative incidence of OS will be estimated by the method of Kaplan-Meier. | Throughout the study period, approximately 3 years per patient |
| Frequency of serious adverse events (SAEs) | Percentage of patients who experience SAEs during the study | Throughout the study period, approximately 3 years per patient |
| Rate of complications associated with plasma exchange treatment | Percentage of patients who experience complications associated with plasma exchange | Throughout the study period, approximately 3 years per patient |
| Frequency of complications associated with plasma exchange treatment | Number of complications associated with plasma exchange per TTP event | Throughout the study period, approximately 3 years per patient |
| Hospital Universitario Bellvitge | Recruiting | L'Hospitalet de Llobregat | Barcelona | 08907 | Spain |
|
| Hospital Clínic Barcelona | Recruiting | Barcelona | 08036 | Spain |
|
| Hospital Universitario de Guadalajara | Recruiting | Guadalajara | 19002 | Spain |
|
| Hospital Universitario La Paz | Recruiting | Madrid | 28046 | Spain |
|
| Hospital Virgen de la Arrixaca | Recruiting | Murcia | 30120 | Spain |
|
| Hospital Clínico Universitario de Valencia | Recruiting | Valencia | 46010 | Spain |
|
| D057049 |
| Thrombotic Microangiopathies |
| D013921 | Thrombocytopenia |
| D001791 | Blood Platelet Disorders |
| D000095542 | Cytopenia |
| D007154 | Immune System Diseases |
| D006470 | Hemorrhage |
| D010335 | Pathologic Processes |
| D013568 | Pathological Conditions, Signs and Symptoms |
| D012877 | Skin Manifestations |
| D012816 | Signs and Symptoms |
| D019851 | Thrombophilia |